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EVALUATION OF DIFFERENCES IN S. PNEUMONIAE COLONIZATION  
 
AMONG CHILDREN WITH AND WITHOUT CLINICALLY 
 
DIAGNOSED ASTHMA/WHEEZE 
 
MUSHENG ALISHAHI 
 
ABSTRACT 
Streptococcus pneumoniae colonization is the nasopharynx is common in young children. 
Colonization of S. pneumoniae is a necessary precursor for invasive pneumococcal 
disease (IPD), which is a major cause of morbidity and mortality among children less 
than five years of age globally. Co-morbidities such as asthma have been identified as 
risk factors for IPD but little is known about why. Children with co-morbidities have a 
higher likelihood of progressing to IPD because they are colonized at higher rates or 
because their immune systems respond differently than children without co-morbidities. 
In addition, vaccination was introduced in 2010 to help decrease pneumococcal 
colonization rates from the 13 most common serotypes. We used data from the pediatric 
primary care clinic at Boston Medical Center to study the relationship between 
asthma/wheeze and S. pneumoniae colonization among children under the age of five 
years. Information about colonization serotype distribution was also assessed in this 
study. Data was accessed from 3098 children from 4–59 months old visiting the pediatric 
primary care clinic at Boston Medical Center from July 2010 to March 2014. In 
multivariable logistic regression models, the odds of colonization increased 80% (OR 
1.80, 95% CI 1.2, 2.6) in children with asthma/wheeze under 24 months old. Adjustment 
for presence of URTI or recent exposure to antibiotics slightly mitigates this relationship. 
		 vii 
Children with clinically diagnosed asthma/wheeze have 80% increased odds of being 
colonized than children without asthma/wheeze. 
  
		 viii 
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Background 
Nasopharyngeal colonization with the bacterium Streptococcus pneumoniae 
(pneumococcus) is a necessary precursor for the development of invasive pneumococcal 
disease (IPD).  IPD is a major cause of global morbidity and mortality among children 
under five years old 2,3. IPD manifests as bacteremia, meningitis, or bacteremic 
pneumonia, depending on the site of infection. There are 92 pneumococcal serotypes 
known to cause IPD; however, most IPD cases are attributed to only a few serotypes3. In 
2000, the United States began widespread use of heptavalent pneumococcal conjugate 
vaccine (PCV7) in children to protect against the seven pneumococcal serotypes most 
frequently found in IPD cases. After the introduction of PCV7, the distribution of S. 
pneumoniae serotypes in the community changed: vaccine serotypes decreased and non-
vaccine serotypes increased, creating the need for a pneumococcal vaccine with 
additional serotype coverage7.  The pneumococcal vaccine in current use is a 13-valent 
pneumococcal conjugate vaccine (PCV13) that protects against the 13 pneumococcal 
serotypes that accounted for nearly 90% of all IPD cases in the United States prior to 
20106. The use of pneumococcal conjugate vaccines (PCVs) has been very effective in 
decreasing the prevalence of IPD in the United States thus far. However, as PCV13 use 
continues, the distribution of pneumococcal serotypes circulating in the community may 
continue to shift, which could ultimately lead to an increase in IPD cases caused by non-
vaccine serotypes.   
 Children with underlying co-morbidities are at increased risk of developing IPD 4. 
Although most children who are colonized with pneumococcus during childhood never 
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progress to IPD, 11–44% of children with IPD have an underlying co-morbidity. In 
addition to being at increased risk for IPD, children with underlying co-morbidities also 
have a higher likelihood of recurrent IPD and IPD-related death9, 10, 11. The co-morbidities 
that have been associated with increased risk of IPD in children include anatomic or 
functional asplenia, congenital and acquired immunodeficiency, anatomical 
abnormalities, nephrotic syndrome, and asthma12. As the prevalence of chronic disease 
among children increases in the United States, it is important to consider the impact this 
could have on the number of IPD cases8. It is currently not known whether children with 
co-morbidities are at a higher risk of IPD because they are colonized with S. pneumoniae 
at higher rates or because they are more likely to develop IPD once they are colonized. 
The overall objective of this study is to advance the current state of knowledge about why 
children with comorbidities are at increased risk for developing IPD by comparing S. 
pneumoniae colonization patterns among children with and without comorbidities. 
Specifically, we evaluated whether young children with clinically diagnosed 
asthma/wheeze — a relatively common childhood comorbidity — were more likely to 
carry S. pneumoniae in their nasopharynx compared with young children without 
asthma/wheeze, and whether there were differences in serotype distributions in these two 
populations. 
Methods 
Study Population 
 The data source for this analysis was an ongoing pneumococcal colonization 
surveillance study that began in 2010. The goal of this surveillance study is to describe 
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the overall and serotype-specific prevalence of pneumococci in the nasopharynx of 
children aged 4 to 59 months who attend the pediatric primary care clinic at Boston 
Medical Center (BMC). The BMC pediatric primary care clinic is the largest provider of 
care for Boston’s urban population and serves nearly 6,000 families with young children, 
resulting in ~25,000 annual visits.  
 The study population comprised 3,098 children aged 4 to 59 months who attended 
the BMC pediatric primary care clinic at least once between July 2010 and March 2014 
who presented with a non-toxic appearance and were accompanied by an adult care-giver 
who could provide informed consent in English or Spanish. Patient recruitment was 
designed to ensure that approximately 25% of the study population was aged 4 to 11 
months, 25% was 12 to 23 months, and 50% was 24 to 59 months. Parents of children 
who agreed to participate completed a brief questionnaire and provided consent for study 
investigators to collect nasopharyngeal swabs from their child and to access to their 
child’s medical record to obtain information about medications and presence of 
asthma/wheeze. Demographic information collected via questionnaire included child age 
at enrollment, sex, race/ethnicity, parent education level, and parent income level. Other 
health information was also collected: breastfeeding history, recent history of illness — 
such as upper respiratory infection —, recent exposure to antibiotics and/or other 
medications, presence of young siblings in the household, group childcare attendance, 
and exposure to adults who smoke in the household. Information about pneumococcal 
vaccinations included the vaccine formulation (PCV7 or PCV13) and date(s) of 
administration. Nasopharyngeal swabs were processed within one day using standard 
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microbiologic approaches for pneumococcal culture, serotype identification, and 
evaluation of antimicrobial susceptibility if the culture was positive for S. pneumoniae. 
For children who visited the BMC pediatric primary care clinic more than one time 
during the study period, information was only obtained from their first visit and 
subsequent visits were ignored.  
Study Measures 
 Diagnosis of asthma/wheeze was the exposure of interest in this study, and was 
assessed via a two-step process. First, electronic medical records were assessed for 
evidence of an asthma ICD-9 diagnosis code (ICD-9 493.0). Next, a qualified clinician 
reviewed these charts to confirm the presence of asthma/wheeze by identifying one or 
more of the following: prescription for asthma medication within 30 days of asthma 
diagnosis code; a second asthma diagnosis code within ±12 months; a positive finding for 
an asthma diagnostic test such as forced expiratory volume (FEV1). Children with 
evidence of both an asthma diagnosis code and one or more of the clinical asthma 
characteristics listed above were classified as having confirmed asthma/wheeze. Children 
who had evidence of an asthma diagnosis code by none of the clinical asthma 
characteristics listed above were classified as having possible asthma/wheeze, and 
children with no asthma diagnosis code were classified as not having asthma/wheeze. 
Study subjects with probable and confirmed cases of asthma/wheeze were compared to 
individuals without an asthma/wheeze diagnosis on demographic factors and presence of 
S. pneumoniae.  
 A positive culture for S. pneumoniae was the outcome for this study. Children 
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who had a positive S. pneumoniae culture were further classified by whether they were 
colonized with a vaccine serotype (VST) or a non-vaccine serotype (NVST), and by 
individual serotypes. 
Statistical Analysis  
 Two-sample t-tests (continuous variables) and chi-squared tests (categorical 
variables) were used to compare children with and without asthma/wheeze by age, sex, 
race, ethnicity, breastfeeding history, exposure to smoking, recent use of antibiotics, 
current upper respiratory tract infection, number of children living in the household, 
parent education level, and parent income level. Two-sided p-values <0.05 were 
considered statistically significant.  
 Logistic regression was used to estimate crude and adjusted associations between 
asthma/wheeze and S. pneumoniae colonization. Demographic and clinical characteristics 
defined above were evaluated as potential confounders; age, presence of upper 
respiratory tract infection (RTI) at time of visit, and recent exposure to antibiotics were 
accounted for in final models.  Specifically, logistic regression models were built 
considering asthma/wheeze as the main exposure and adding presence of RTI and recent 
exposure to antibiotics individually into the model to assess for further confounding. 
Models were built by adding each confounder to the crude model and assessing for a 10% 
change in the odds ratio. Each potential confounder was added to the model until the 
model included every variable. All models were stratified by age (<24 months and > 24 
months old) to assess if age was having a differential impact on the outcome of 
colonization. We tested for interactions between asthma/wheeze, RTI, and recent 
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exposure to antibiotics. Finally, among children with positive S. pneumoniae cultures, we 
compared the serotype distributions in children with and without asthma/wheeze. All 
analyses were conducted using Microsoft Excel and SAS version 9.4. 
 
Ethical Issues 
 This study was approved by the Boston Medical Center Internal Review Board 
and all identifying information was removed from the data set before it was received by 
study investigators.  
Results 
Characteristics of the Study Population 
 The study population included 3098 children 4 to 59 months; 34.2% were aged 4 
to 11 months, 20.8% were 12 to 23 months, 14.3% were 24 to 35 months, 14.9% were 36 
to 47 months, and 15.8% were 48 to 59 months. Approximately half (55%) of the study 
population was less than 24 months of age, and approximately half (45%) was 24 months 
or older. The overall study population consisted of 50.8% male and 49.2% female. Most 
the study subjects identified as racially Black (68.6%) and ethnically non-Hispanic 
(79.1%). Parent income level for participating children was indicative of the urban 
population that BMC serves, with 67% of parents making less than $35,000 a year. 
Similarly, 48.5% of the overall study population had parents with an education level of 
high school graduate/GED or less than a 12th grade education. Recent exposure to 
antibiotics (within 2 months of visit to pediatric primary care clinic) was apparent in 
10.9% of the population. Among children in the study population, 41.9% of study 
participants reported an upper respiratory tract infection at the time of their visit to the 
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pediatric primary care clinic. Overall, 80.1% of children’s caregivers indicated that they 
had been breastfed for some period of time, and 27.4% of children were exposed to 
smoking. Characteristics of the study population are shown in Table 1. 
Characteristics of Children with Asthma/Wheeze 
 In total, 372 (12.0%) children were classified as having confirmed 
asthma/wheeze. Children with asthma/wheeze tended to be older than children without 
asthma/wheeze (62.6% of children with asthma were ≥24 months vs. 42.6% of children 
without asthma/wheeze, p<0.001). Compared to children who did not have 
asthma/wheeze, children with asthma wheeze were more likely to be male (56.2% vs. 
50.0%, p=0.027), less likely to have been breastfed (71.5% vs. 81.3%, p<0.0001), more 
likely to have had recent exposure to antibiotics (14.0% vs. 10.5%, p=0.05), and more 
likely to have a current upper respiratory tract infection (51.3% vs. 40.6%, p<0.0001) 
(Table 1). 
 
Nasopharyngeal Colonization of S. pneumoniae and serotype distribution 
S. pneumoniae was recovered from 21.8% (n=675) of children in the study population; 81 
isolates were VST (12%) and 594 were NVST (88%). Figure 1 shows the distribution of 
pneumococcal colonization among children with and without asthma/wheeze. Children 
with asthma/wheeze were more likely to be colonized than children without 
asthma/wheeze (24.2% vs. 21.5%), but this difference was not statistically significant 
(p=0.23).   
Stratification of the study population into children <24 months and ≥24 months 
suggested that the association between asthma/wheeze and pneumococcal colonization 
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may differ by age. Children <24 months of age who were diagnosed with asthma/wheeze 
had an 80% increased odds of pneumococcal colonization compared to children who did 
not have asthma/wheeze (OR=1.80; 95% CI 1.2 – 2.6). Adjusting for presence of upper 
respiratory tract infection explained a small part of this effect, but asthma/wheeze still 
was associated with a 60% increased odds of colonization after adjustment (OR=1.6, 95% 
CI: 1.1, 2.4). The same associations were not seen in children ≥24 months (Table 2).  
 Children in the study population were colonized by 38 different serotypes: 9 of 13 
VST, and 29 NVST. Add a sentence comparing the proportion of VST in each group. 
Differences between serotype distributions in children with and without asthma/wheeze 
were most notable for serotypes 19F (6.7% vs. 4.4%), 23F (4.4% vs. 22%), 15BC (5.6% 
vs. 3.9%), 16F (18.9% vs. 14.7%), and 38 (2.2% vs. 0.7%) (Figure 2). 
 
Discussion 
 The findings from this study suggest that there may be an association between 
asthma/wheeze and S. pneumoniae colonization among children under 24 months of age, 
even after adjusting for current upper respiratory tract infection and recent use of 
antibiotics. This same association was not observed in older children. We also observed 
increased prevalence of colonization with serotypes 19F, 23, 15BC, 16F, and 38 among 
children with asthma/wheeze, suggesting that increased colonization with these NVST 
may be responsible for the increased colonization among children with asthma/wheeze.  
 Exposure to smoking, breastfeeding, and other young children in the household 
have been demonstrated to increase the risk of S. pneumoniae colonization. Asthma has 
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been identified as a risk-factor for nasopharyngeal colonization of Streptococcus 
pneumoniae in adolescents13. However, evidence of this finding has not been previously 
studied in young children (under age 5 years).  
 The findings of this study show that children under 24 months with 
asthma/wheeze had an 80% increased odds of being colonized. Adjustment for presence 
of URTI or recent exposure to antibiotics slightly mitigates this relationship. It has been 
previously shown that nasopharyngeal bacterial colonization including S. pneumoniae, S. 
aureus, M. catarrhalis, S. pyogenes, and H. influenzae is associated with asthma, and 
prior evidence suggests that there is an underlying immune response that is lacking in 
children with asthma/wheeze that increases their risk of pneumococcal colonization13, 14. 
This study does not seem to indicate that there are differences in incidences of 
pneumococcal colonization among children with and without asthma/wheeze except for 
children under the age of 24 months. It is important to note, however, that it is difficult to 
diagnose asthma/wheeze in very young children because children’s immune functions 
mature as they get older and issues with asthma/wheeze can subside with age. On the 
other hand, asthma diagnoses can become more common as a child gets older without 
showing symptoms in their first two years. This study suggest that there may be an 
underlying cause of colonization in children under 24 months that is associated with 
respiratory inflammation such as URTI. A previous study by Esposito et al.15 suggested 
that asthmatic children have a poor immune response to the pneumococcal antigen which 
may impact their likelihood to be colonized and further progress to IPD. The increased 
odds of colonization were strictly related to age group and the association was slightly 
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attenuated when adjusted for upper respiratory tract infection.  
 The proportion of the study population colonized with S. pneumoniae was 21.8%, 
which is consistent with colonization rates in the U.S.6. There were slightly different 
proportions of colonization among children with and without asthma/wheeze with respect 
to serotypes 19F, 23F, 15BC, 16F, and 38. Of these serotypes only 19F is a vaccine 
serotype, but is also a serotype that has been identified to cause pneumonia among 
children16. Even with vaccine protection, there are higher proportions of children with 
asthma/wheeze being colonized compared to children without asthma/wheeze. Non-
vaccine serotypes are seen in high proportions in this study population, which suggests 
that colonization patterns are shifting away from the serotypes included in PCV13 as 
expected. This information is important for the future control and prevention of IPD 
among children with chronic conditions such as asthma/wheeze because we know that 
colonization is a necessary precursor for IPD to develop.   
 This study included a large cohort of children from the pediatric primary care 
clinic at Boston Medical Center, which serves a generally under-represented population. 
This research provides valuable information about the association of asthma/wheeze and 
S. pneumoniae colonization for U.S. urban communities that have similar demographics 
and incidence rates of pneumococcal colonization. Limitations of this study include 
possible information bias and misclassification of asthma/wheeze. Bias due to self-
reporting could lead to incorrect classification of health information such as recent 
exposure to antibiotics, in addition, it is possible that poor recall of a child’s medical 
history impacted the quality of information reported.  Misclassification bias for 
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determination of S. pneumoniae colonization was probably unlikely due to the 
standardize protocol for specimen testing, however, misclassification bias was probable 
for asthma/wheeze diagnosis. Although a qualified clinician performed comprehensive 
reviews of medical records, asthma/wheeze diagnosis in young children is difficult to 
confirm. An underestimation of asthma/wheeze is possible because the information was 
ascertained from medical records with ICD-9 codes, however, it is possible that there 
were cases of probable asthma/wheeze that were missed if an ICD-9 code was absent. In 
addition, due to the nature of asthma/wheeze in young children, it is possible that a 
child’s wheeze was not indicative of asthma-like symptoms (surrogate for co-morbidity) 
and was caused by an un-related illness. Another limitation of this study is the use of 
existing data which can introduce confounding because of the lack of temporality. Some 
children in the study population visited the pediatric primary care clinic multiple times 
but information was only taken from the first visit which could lead to misclassification 
bias of either asthma/wheeze or colonization. 
 The results from this study yield important information about the association 
between asthma/wheeze and S. pneumoniae colonization because this association has not 
been explored in young children. Previous information suggests that pneumococcal 
colonization is associated with increased risk of asthma/wheeze but information is 
lacking regarding the risk of pneumococcal colonization for children with 
asthma/wheeze. It is known that young children with asthma/wheeze are more likely to 
be colonized but the reason or mechanism is largely unexplored. Further research 
involving the associated risks of asthma/wheeze and pneumococcal colonization within 
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children under age five are necessary to further investigate whether asthma/wheeze is a 
risk-factor for colonization because of an altered immune response or because there is 
differential exposure to S. pneumoniae for children with asthma/wheeze at young ages. 
Evidence from this study suggests there is a growing distribution of pneumococcal 
colonization of non-vaccine serotypes. In this study population, 88.2% of all colonization 
was a NVST, which suggests there is a substantial shift in colonization patterns and 
suggests that PCV13 may not be adequate to protect against IPD. The shift in 
colonization patterns is pertinent public health information, but further investigation 
should continue to understand how these shifts in colonization patterns are impacting 
prevalence of IPD. 
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APPENDIX A 
Table 1. Characteristics of the study population; Boston, MA; July 2010 – March 2014. 
 
Characteristic Overall Study 
Population 
(N=3098) 
Asthma/Wheeze 
(N=372) 
No 
Asthma/Wheeze 
(N=2726) 
p-value 
Age, months (mean ± SD) 24.0 ± 17.5 31.12 ± 17.47 23.1 ± 17.3 <0.0001 
S.pneumoniae colonization 
     Positive 
     Negative 
 
675 (21.8) 
2423 (78.2) 
 
90 (24.2) 
282 (75.2) 
 
585 (21.5) 
2141 (78.5) 
0.2360 
Age Group (n, %) 
     4–11 months 
     12–23 months 
     24–35 months 
     36–47 months 
     48–59 months 
 
1060 (34.2) 
645 (20.8) 
444 (14.3) 
460 (14.9) 
489 (15.8) 
 
70 (18.8) 
69 (18.6) 
61 (16.4) 
80 (21.5) 
92 (24.7) 
 
990 (36.6) 
576 (21.1) 
383 (14.1) 
380 (13.9) 
398 (14.6) 
<0.0001 
Sex (n, %) 
     Male 
     Female 
 
1573 (50.8) 
1525 (49.2) 
 
209 (56.2) 
163 (43.8) 
 
1364 (50.0) 
1362 (50.0) 
 
0.0271 
Race (n, %) 
     Black 
     White 
     Asian 
     American Indian 
     Other 
 
2126 (68.6) 
299 (9.7) 
94 (3.0) 
8 (0.3) 
570 (18.4) 
 
276 (74.2) 
21 (5.7) 
7 (1.9) 
1 (0.3) 
67 (18.0) 
 
1850 (67.9) 
278 (10.2) 
87 (3.2) 
7 (0.3) 
503 (18.5) 
0.0521 
Ethnicity (n, %) 
    Hispanic 
    Non-Hispanic 
    No answer 
 
646 (20.8) 
2451 (79.1) 
1 (0.03) 
 
89 (23.9) 
283 (76.1) 
0 (0.0) 
 
557 (20.4) 
2168 (79.5) 
1 (0.1) 
0.2802 
Breastfed (n, %) 
    No 
    Yes 
 
616 (19.9) 
2482 (80.1) 
 
106 (28.5) 
266 (71.5) 
 
510 (18.7) 
2216 (81.3) 
<0.0001 
Exposure to smoking (n, %) 
    No 
    Yes 
 
2248 (72.6) 
850 (27.4) 
 
253 (68.0) 
119 (32.0) 
 
1995 (73.2) 
731 (26.8) 
0.0408 
Antibiotic use in past 2 months  
(n, %) 
  No    
  Yes 
 
2760 (89.1) 
338 (10.9) 
 
320 (86.0) 
52 (14.0) 
 
2440 (89.5) 
286 (10.5) 
0.0508 
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RTI (n, %) 
  No 
  Yes 
 
1800 (58.1) 
1298 (41.9) 
 
181 (48.7) 
191 (51.3) 
 
1619 (59.4) 
1107 (40.6) 
<0.0001 
Number of children in household 
(mean ± SD) 
 
2.09 ± 1.20 
 
2.15 ± 1.22 
 
2.08 ± 1.20 
0.3114 
Parent education level (n, %) 
  Less than 12th grade 
  High school graduate/GED 
  Some college 
  College graduate 
  Unknown/unreported 
 
421 (13.6) 
1080 (34.9) 
866 (28.0) 
723 (23.3) 
8 (0.3) 
 
43 (11.6) 
147 (39.5) 
121 (32.5) 
60 (16.1) 
1 (0.3) 
 
378 (13.9) 
933 (34.2) 
745 (27.3) 
663 (24.3) 
7 (0.3) 
0.0024 
Parent income level (n, %) 
  <$35,000 
  $35,000–$49,000 
  $50,000–$74,000 
  $75,000–$99,000 
  $100,000+ 
  Unknown/unreported 
 
2075 (67.0) 
390 (12.6) 
205 (6.6) 
98 (3.2) 
148 (4.8) 
182 (5.9) 
 
254 (68.3) 
57 (5.3) 
25 (6.7) 
8 (2.2) 
8 (2.2) 
20 (5.4) 
 
1821 (66.8) 
333 (12.2) 
180 (6.6) 
90 (3.3) 
140 (5.1) 
162 (5.9) 
0.0677 
*Subjects who had confirmed and probable diagnosis of asthma/wheeze are included in 
the asthma/wheeze category. 
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APPENDIX B		
Table 2. Adjusted association between asthma/wheeze and S. pneumoniae colonization 
among children 4 to 59 months; Boston, MA; July 2010 – March 2014. 
 
Association of asthma/wheeze 
and colonization 
Odds Ratio (95% CI)  
– Children < 24 months 
Odds Ratio (95% CI) 
Children ≥ 24 months 
Adjusted for age group 1.8 (1.2, 2.6) 0.9 (0.6, 1.2) 
Adjusted for age group and URTI 1.6 (1.1, 2.4) 0.7 (0.5, 1.1) 
Adjusted for age group, URTI, 
and recent antibiotic use 1.7 (1.1, 2.5) 0.7 (0.5, 1.1) 				*	URTI:	Upper	respiratory	tract	infection				 	
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APPENDIX C 	
Figure 1. Distribution of Streptococcus pneumoniae colonization among children aged 4 
to 59 months with and without asthma/wheeze; Boston, MA; July 2010 to March 2014 
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APPENDIX D 
 
Figure 2. Comparison of proportions of S. pneumoniae serotype for children (4–59 
months) with and without asthma/wheeze; Boston, MA. 
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